Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

$3.7B

Market Cap • 12/26/2024

2022

(2 years)
Founded

2022

(2 years ago)
IPO

NYSE

Listing Exchange
Flag of US

New Haven

Headquarters • Connecticut